Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

医学 耐受性 内科学 间质性肺病 类风湿性关节炎 吡非尼酮 安慰剂 双盲 关节炎 不利影响 特发性肺纤维化 病理 替代医学
作者
Joshua J. Solomon,Sonye K. Danoff,Felix Woodhead,Shelley Hurwitz,Rie Maurer,Ian Glaspole,Paul F. Dellaripa,Bibek Gooptu,Robert Vassallo,Gerard Cox,Kevin R. Flaherty,Huzaifa Adamali,Michael Gibbons,Lauren Troy,Ian Forrest,Joseph A. Lasky,Lisa Spencer,Jeffrey A. Golden,Mary Beth Scholand,Nazia Chaudhuri
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:11 (1): 87-96 被引量:133
标识
DOI:10.1016/s2213-2600(22)00260-0
摘要

Summary

Background

Interstitial lung disease is a known complication of rheumatoid arthritis, with a lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety, tolerability, and efficacy of pirfenidone for the treatment of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Methods

TRAIL1 was a randomised, double-blind, placebo-controlled, phase 2 trial done in 34 academic centres specialising in interstitial lung disease in four countries (the UK, the USA, Australia, and Canada). Adults aged 18–85 years were eligible for inclusion if they met the 2010 American College of Rheumatology and European Alliance of Associations for Rheumatology criteria for rheumatoid arthritis and had interstitial lung disease on a high-resolution CT scan imaging and, when available, lung biopsy. Exclusion criteria include smoking, clinical history of other known causes of interstitial lung disease, and coexistant clinically significant COPD or asthma. Patients were randomly assigned (1:1) to receive 2403 mg oral pirfenidone (pirfenidone group) or placebo (placebo group) daily. The primary endpoint was the incidence of the composite endpoint of a decline from baseline in percent predicted forced vital capacity (FVC%) of 10% or more or death during the 52-week treatment period assessed in the intention-to-treat population. Key secondary endpoints included change in absolute and FVC% over 52 weeks, the proportion of patients with a decline in FVC% of 10% or more, and the frequency of progression as defined by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02808871.

Findings

From May 15, 2017, to March 31, 2020, 231 patients were assessed for inclusion, of whom 123 patients were randomly assigned (63 [51%] to the pirfenidone group and 60 [49%] to the placebo group). The trial was stopped early (March 31, 2020) due to slow recruitment and the COVID-19 pandemic. The difference in the proportion of patients who met the composite primary endpoint (decline in FVC% from baseline of 10% or more or death) between the two groups was not significant (seven [11%] of 63 patients in the pirfenidone group vs nine [15%] of 60 patients in the placebo group; OR 0·67 [95% CI 0·22 to 2·03]; p=0·48). Compared with the placebo group, patients in the pirfenidone group had a slower rate of decline in lung function, measured by estimated annual change in absolute FVC (–66 vs –146; p=0·0082) and FVC% (–1·02 vs –3·21; p=0·0028). The groups were similar with regards to the decline in FVC% by 10% or more (five [8%] participants in the pirfenidone group vs seven [12%] in the placebo group; OR 0·52 [95% CI 0·14–1·90]; p=0·32) and the frequency of progression as defined by OMERACT (16 [25%] in the pirfenidone group vs 19 [32%] in the placebo group; OR 0·68 [0·30–1·54]; p=0·35). There was no significant difference in the rate of treatment-emergent serious adverse events between the two groups, and there were no treatment-related deaths.

Interpretation

Due to early termination of the study and underpowering, the results should be interpreted with caution. Despite not meeting the composite primary endpoint, pirfenidone slowed the rate of decline of FVC over time in patients with RA-ILD. Safety in patients with RA-ILD was similar to that seen in other pirfenidone trials.

Funding

Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Imp完成签到,获得积分10
1秒前
1秒前
2秒前
量子星尘发布了新的文献求助10
2秒前
3秒前
33发布了新的文献求助30
3秒前
彦卿完成签到 ,获得积分10
4秒前
思源应助赵清持采纳,获得10
5秒前
张雯思发布了新的文献求助10
6秒前
Orange应助Shrine采纳,获得10
7秒前
8秒前
卡卡罗特发布了新的文献求助10
8秒前
cdytjt完成签到,获得积分10
10秒前
13秒前
ding应助小田心采纳,获得10
13秒前
13秒前
13秒前
14秒前
14秒前
wwl发布了新的文献求助10
15秒前
鹏程万里完成签到,获得积分10
16秒前
星辰大海应助li采纳,获得10
17秒前
chasikan发布了新的文献求助30
18秒前
cxy发布了新的文献求助10
19秒前
幸福大白发布了新的文献求助10
20秒前
大个应助贾克斯采纳,获得10
22秒前
过时的画板完成签到,获得积分10
22秒前
大气小蘑菇完成签到,获得积分10
25秒前
26秒前
小田心发布了新的文献求助10
32秒前
千跃举报求助违规成功
32秒前
whatever举报求助违规成功
32秒前
wdy111举报求助违规成功
32秒前
32秒前
tongluobing完成签到,获得积分10
33秒前
我是老大应助深情的雁露采纳,获得10
34秒前
35秒前
Singularity应助爱笑晓曼采纳,获得20
35秒前
量子星尘发布了新的文献求助10
36秒前
37秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174